title: Increased plasma apoM levels in the patients suffered from hepatocellular carcinoma and other chronic liver diseases.
abstract: OBJECTIVE
  To determine plasma apolipoprotein M (apoM) levels and other lipid profiles in hepatocellular carcinoma (HCC) patients compared to other chronic liver diseases and normal subjects.
  
  
  METHODS
  36 HCC, 68 chronic hepatitis, 29 liver cirrhosis patients and 64 normal controls were subjected in the present study. Serum lipids, lipoproteins, apolipoprotein AI (apoAI) and apoB were determined by the conventional methods. Plasma apoM levels were semi-quantitatively determined by both dot-blotting and western blotting analysis.
  
  
  RESULTS
  Serum levels of triglycerides (TG), HDL-cholesterol, apoAI and lipoprotein (a) (Lp(a)) were significantly lower in the HCC patients than in the normal subjects, whereas there were no obvious differences on serum total cholesterol, LDL-cholesterol and apoB between HCC patients and normal subjects. However, plasma apoM levels in HCC patients were significantly increased than those in the normal subjects, but lower than those in the chronic hepatitis and cirrhosis patients.
  
  
  CONCLUSIONS
  It is concluded that serum TG, apoAI, HDL-C and Lp(a) were significantly decreased in HCC patients than in controls, whereas plasma apoM levels were significantly increased in the HCC patients. Decreased serum TG, apoAI, HDL-C and Lp(a) may reflect the liver damage in HCC patients, whereas the clinical significance of increased plasma apoM levels in relation to HCC is not clear.
authors.affiliation: Department of Tumor Biological Treatment, The Third Affiliated Hospital of Suzhou University, Changzhou 213003, PR China. jjtnew@163.com
authors.forename: Jingting
authors.initials: J
authors.lastname: Jiang
authors.forename: Xiaoying
authors.initials: X
authors.lastname: Zhang
authors.forename: Changping
authors.initials: C
authors.lastname: Wu
authors.forename: Xihu
authors.initials: X
authors.lastname: Qin
authors.forename: Guanghua
authors.initials: G
authors.lastname: Luo
authors.forename: Haifeng
authors.initials: H
authors.lastname: Deng
authors.forename: Minyang
authors.initials: M
authors.lastname: Lu
authors.forename: Bin
authors.initials: B
authors.lastname: Xu
authors.forename: Min
authors.initials: M
authors.lastname: Li
authors.forename: Mei
authors.initials: M
authors.lastname: Ji
authors.forename: Ning
authors.initials: N
authors.lastname: Xu
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D001053:Apolipoproteins / Q000097:blood*; D000075243:Apolipoproteins M; D006528:Carcinoma, Hepatocellular / Q000097:blood*; D016022:Case-Control Studies; D002908:Chronic Disease; D005260:Female; D006505:Hepatitis; D006801:Humans; D054834:Lipocalins; D008103:Liver Cirrhosis; D008107:Liver Diseases / Q000097:blood*; D008297:Male; D008875:Middle Aged
chemical_list: C400523:APOM protein, human; D001053:Apolipoproteins; D000075243:Apolipoproteins M; D054834:Lipocalins